<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363855</url>
  </required_header>
  <id_info>
    <org_study_id>17719</org_study_id>
    <nct_id>NCT02363855</nct_id>
  </id_info>
  <brief_title>Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects</brief_title>
  <official_title>An Open Label Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY 1841788 in Japanese Subjects With Metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to investigate the safety and tolerability of BAY
      1841788 in Japanese subjects with metastatic castration-resistant prostate cancer (mCRPC) and
      the PK of BAY 1841788 and its major metabolite BAY 1896953.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug product is licensed from Orion pharma, Finland which is also the manufacturer of the
      product.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2015</start_date>
  <completion_date type="Actual">January 18, 2018</completion_date>
  <primary_completion_date type="Actual">November 19, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Treatment Emergent Adverse Event as measure of safety and tolerability</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The intensity of an adverse event graded using the NCI CTCAE version 4.03</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of BAY 1841788 characterized by Cmax</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>Cmax: maximum drug concentration in plasma after single dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of BAY 1841788 characterized by tmax</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>tmax: time to reach maximum drug concentration in plasma after single (first) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of BAY 1841788 characterized by AUC(0-12)</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>AUC(0-12):AUC from time 0 to 12 hours after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of metabolite BAY 1896953 characterized by Cmax</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>Cmax: maximum drug concentration in plasma after single dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of metabolite BAY 1896953 characterized by tmax</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>tmax: time to reach maximum drug concentration in plasma after single (first) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of metabolite BAY 1896953 characterized by AUC(0-12)</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>AUC(0-12):AUC from time 0 to 12 hours after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of diastereomers BAY 1896951 characterized by Cmax</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>Cmax: maximum drug concentration in plasma after single dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of diastereomers BAY 1896951 characterized by tmax</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>tmax: time to reach maximum drug concentration in plasma after single (first) dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of diastereomers BAY 1896951 characterized by AUC(0-12)</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>AUC(0-12):AUC from time 0 to 12 hours after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of diastereomers BAY 1896952 characterized by Cmax</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>Cmax: maximum drug concentration in plasma after single dose administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of diastereomers BAY 1896952 characterized by tmax</measure>
    <time_frame>tmax: time to reach maximum drug concentration in plasma after single (first) dose</time_frame>
    <description>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of diastereomers BAY 1896952 characterized by AUC(0-12)</measure>
    <time_frame>Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}</time_frame>
    <description>AUC(0-12):AUC from time 0 to 12 hours after administration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>BAY 1841788(ODM-201)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Safety, tolerability and PK of 300 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 28 days after start of multiple dose (MD) Cohort 2: Safety, tolerability and PK of 600 mg dose given twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 1841788(ODM-201)</intervention_name>
    <description>Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.</description>
    <arm_group_label>BAY 1841788(ODM-201)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese males aged ≥ 20 years

          -  Histologically or cytologically confirmed adenocarcinoma of prostate without
             neuroendocrine differentiation or small cell features

          -  Patients with metastatic castration-resistant prostate cancer (mCRPC). CRPC is defined
             as follows

               -  Ongoing androgen deprivation therapy with a luteinizing hormone-releasing hormone
                  (LHRH) analogue or antagonist, or bilateral orchiectomy, and castrate level of
                  serum testosterone (&lt; 1.7 nmol/l [50 ng/dL]) at screening AND

               -  Progressive disease and/or prostate-specific antigen (PSA) increase of three
                  consecutive rises, at least 1 week apart AND

               -  PSA &gt; 2ng/mL at screening

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1

          -  Life expectancy of at least 3 months

          -  Blood counts at screening: haemoglobin ≥ 9.0 g/dL, absolute neutrophil count ≥
             1,500/μL (1.5x109/l), platelet count ≥ 100,000/μL (100x109/l) (patient must not have
             received any growth factor or blood transfusion within 7 days of the hematology
             laboratory obtained at screening)

          -  Screening values of serum alanine aminotransferase (ALT) and/or aspartate transaminase
             (AST) ≤ 2.5 x upper limit of normal (ULN), total bilirubin ≤ 1.5 x ULN, creatinine ≤
             1.5 x ULN, albumin &gt; 3.0 g/dl

          -  Prior treatment with antiandrogen. Discontinuation of bicalutamide or nilutamide (not
             approved in Japan) at least 6 weeks and other antiandrogens at least 4 weeks prior to
             the start of the study drug administration.

        Exclusion Criteria:

          -  Known metastases in the brain

          -  Symptomatic local-regional disease that requires medical intervention including
             moderate/severe urinary obstruction or hydronephrosis due to prostate cancer

          -  Acute toxicities (except for alopecia and CTCAE grade 2 neuropathy) of prior
             treatments and procedures not resolved to CTCAE ≤ grade 1 or baseline before the first
             drug administration

          -  Febrile neutropenia of Common Terminology Criteria for Adverse Events (CTCAE) ≥ 3

          -  History of other malignancy within the previous 5 years except a basal cell carcinoma
             of skin and any other cancer for which treatment has been completed ≥ 5 years ago and
             from which the patient has been disease-free5 years ago and from which the patient has
             been disease-free

          -  Prior treatment within 4 weeks before the first drug administration with
             immunotherapy, antiandrogen, CYP17 inhibitor (CYP17i), oral ketoconazole, estrogens,
             5-α reductase inhibitors or investigational treatment

          -  Use of bicalutamide or nilutamide (not approved in Japan) within 6 weeks before the
             first drug administration

          -  Radiation therapy (external beam radiation therapy [EBRT], brachytherapy, or
             radiopharmaceuticals) or chemotherapy (except for nitrosoureas and mitomycin C) within
             4 weeks before the first drug administration. Use of nitrosoureas or mitomycin C
             within 6 weeks before the first drug administration.

          -  Prior use of any herbal products known to decrease PSA levels (e.g. PC SPES or saw
             palmetto) within 4 weeks before the first drug administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasm Metastasis</keyword>
  <keyword>Metastatic castration-resistant prostate cancer</keyword>
  <keyword>Castration-resistant prostate cancer (CRPC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

